Cord blood mononuclear cell therapy - Beike Biotech

Drug Profile

Cord blood mononuclear cell therapy - Beike Biotech

Alternative Names: UCB-MNC

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beike Biotechnology
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Autistic disorder; Cerebral palsy; Optic nerve disorders; Primary ovarian insufficiency

Most Recent Events

  • 22 Sep 2015 No recent reports of development identified - Clinical-phase for Autistic disorder in China (IM)
  • 22 Sep 2015 No recent reports of development identified - Preclinical for Cerebral palsy in China (IM)
  • 22 Sep 2015 No recent reports of development identified - Preclinical for Optic nerve disorders in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top